Related references
Note: Only part of the references are listed.A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis
Jie Mei et al.
MOLECULAR CANCER (2021)
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
J. Nicholas Bodor et al.
CANCER (2020)
Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis
Xi Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients
Jacqueline Wyss et al.
CLINICAL COLORECTAL CANCER (2019)
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
Yan Li et al.
FRONTIERS IN PHARMACOLOGY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng-Huan Lee et al.
CANCER CELL (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
Subrata Chowdhury et al.
ONCOTARGET (2016)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Microbials for the production of monoclonal antibodies and antibody fragments
Oliver Spadiut et al.
TRENDS IN BIOTECHNOLOGY (2014)
B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma
Dong Hua et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)